Equities

Zhejiang Cheng Yi Pharmaceutical Co Ltd

603811:SHH

Zhejiang Cheng Yi Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)6.21
  • Today's Change-1.90 / -23.43%
  • Shares traded3.92m
  • 1 Year change-42.50%
  • Beta0.9195
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zhejiang Cheng Yi Pharmaceutical Co., Ltd is a China-based company principally engaged in the research, development, production and sales of bulk pharmaceutical chemicals of chemical medicine and preparations. The Company’s products are on the spectrum from arthritis, dieresis to anti-virus and anti-tumor. The main products include bulk pharmaceutical chemicals, injections, capsules, intermediates and others.

  • Revenue in CNY (TTM)732.68m
  • Net income in CNY166.02m
  • Incorporated2001
  • Employees738.00
  • Location
    Zhejiang Cheng Yi Pharmaceutical Co LtdNo. 118 Huagong Road, Dongtou DistrictSHANGHAI 201100ChinaCHN
  • Phone+86 2 133283295
  • Fax+86 2 133283305
  • Websitehttp://www.chengyipharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ginwa Enterprise Group Inc581.53m-15.51m2.57bn553.00--1.69--4.42-0.0382-0.03821.584.070.29684.815.281,051,591.00-0.79160.3641-0.95150.414176.1873.64-2.671.152.190.1960.0431124.25-2.41-5.37-228.19--61.66--
Novoprotein Scientific Inc134.56m-21.29m2.65bn579.00--1.24--19.73-0.3031-0.30311.9230.570.05920.58331.96232,406.80-0.937---0.959--61.17---15.82--34.60--0.0323---42.09---85.84------
Zhejiang Cheng Yi Pharmaceutical Co Ltd732.68m166.02m2.72bn738.0016.402.19--3.720.50720.50722.243.800.40132.0117.68992,793.709.0712.0111.1714.7566.1369.7922.6022.841.01--0.199836.442.544.240.812910.94-23.5612.84
Frontier Biotechnologies Inc133.67m-279.96m2.90bn395.00--2.53--21.72-0.7474-0.74740.35693.070.06361.612.72338,416.90-13.31-14.05-16.40-15.7833.622.35-209.43-450.082.02--0.2808--34.82126.637.79--28.13--
Data as of Sep 13 2024. Currency figures normalised to Zhejiang Cheng Yi Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

1.57%Per cent of shares held by top holders
HolderShares% Held
Rongtong Fund Management Co., Ltd.as of 30 Jun 20241.98m0.61%
China Merchants Fund Management Co., Ltd.as of 30 Jun 20241.57m0.48%
China Southern Asset Management Co., Ltd.as of 30 Jun 2024941.20k0.29%
Gfund Management Co., Ltd.as of 30 Jun 2024347.40k0.11%
Wanjia Asset Management Co., Ltd.as of 30 Jun 202495.30k0.03%
China Asset Management Co., Ltd.as of 30 Jun 202476.90k0.02%
UBS SDIC Fund Management Co., Ltd.as of 30 Jun 202442.72k0.01%
Western Leadbank Fund Management Co., Ltdas of 30 Jun 202440.80k0.01%
Fortune & Royal Asset Management Co., Ltd.as of 30 Jun 202428.50k0.01%
Sealand Securities Co., Ltd. (Investment Management)as of 30 Jun 202421.96k0.01%
More ▼
Data from 30 Jun 2024 - 27 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.